{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:01Z","timestamp":1793394841815,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104817","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:54:10Z","timestamp":1779173650000},"page":"104817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4\/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3363-8512","authenticated-orcid":false,"given":"Letizia","family":"Pontolillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3371-3878","authenticated-orcid":false,"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Pistelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-7087","authenticated-orcid":false,"given":"Antonella","family":"Palazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2884-1632","authenticated-orcid":false,"given":"Nicla","family":"La Verde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-3366","authenticated-orcid":false,"given":"Ida","family":"Paris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Alesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Cannita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Magnolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5368-2400","authenticated-orcid":false,"given":"Laura","family":"Giacinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Raffaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-0963","authenticated-orcid":false,"given":"Luisa","family":"Carbognin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6964-5152","authenticated-orcid":false,"given":"Angela","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Arcuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sangalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7359-5410","authenticated-orcid":false,"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mul\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1150-0345","authenticated-orcid":false,"given":"Carmine","family":"Valenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9529-2960","authenticated-orcid":false,"given":"Rossana","family":"Berardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-1195","authenticated-orcid":false,"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-8033","authenticated-orcid":false,"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.breast.2026.104817_bib2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-Negative breast cancer that progressed on endocrine Therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.breast.2026.104817_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","article-title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up","volume":"174","author":"Rugo","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"10.1016\/j.breast.2026.104817_bib5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.breast.2026.104817_bib6","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"20","key":"10.1016\/j.breast.2026.104817_bib8","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.breast.2026.104817_bib9","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: monaleesa-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104817_bib10","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"Monarch 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104817_bib11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104817_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.breast.2026.104817_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"8042","key":"10.1016\/j.breast.2026.104817_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.breast.2026.104817_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102972","article-title":"Key decision factors in second-line therapy: expert insights on HR+\/HER2-metastatic breast cancer post-CDK4\/6 inhibitor progression","volume":"138","author":"Buonaiuto","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2026.104817_bib16","article-title":"167MO association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): an exploratory analysis of the PADA-1 trial","volume":"33","author":"Rouge","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104817_bib17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2018.08.011","article-title":"Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative metastatic breast cancer in PALOMA-3","volume":"104","author":"Cristofanilli","year":"2018","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.breast.2026.104817_bib18","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low breast cancer: pathological and clinical landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"10.1016\/j.breast.2026.104817_bib19","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104817_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.834651","article-title":"HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer","volume":"9","author":"Venetis","year":"2022","journal-title":"Front Mol Biosci"},{"issue":"7","key":"10.1016\/j.breast.2026.104817_bib22","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s10147-024-02528-w","article-title":"Relationship between HER2-low status and efficacy of CDK4\/6 inhibitors in advanced breast cancer: a real-world study","volume":"29","author":"\u00d6nder","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104817_bib23","first-page":"56","article-title":"The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4\/6 inhibitor and endocrine therapy: a multicentric retrospective study","volume":"70","author":"Caliskan","year":"2023","journal-title":"Breast Off J Eur Soc Mastology"},{"issue":"11","key":"10.1016\/j.breast.2026.104817_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33132","article-title":"The association of ERBB2-Low expression with the efficacy of cyclin-dependent kinase 4\/6 inhibitor in hormone receptor\u2013positive, ERBB2-Negative metastatic breast cancer","volume":"4","author":"Bao","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.breast.2026.104817_bib25","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.3390\/cancers14204981","article-title":"HER2-Low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: results of a multicenter, retrospective cohort study","volume":"14","author":"Carlino","year":"2022","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.breast.2026.104817_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.21873\/cdp.10146","article-title":"Prognostic significance of low HER2 expression in patients with metastatic hormone receptor-positive breast cancer treated with first line CDK4\/6 inhibitors: a Greek multicenter real-world data analysis","volume":"2","author":"Douganiotis","year":"2022","journal-title":"Cancer Diagn Progn"},{"key":"10.1016\/j.breast.2026.104817_bib27","first-page":"541","article-title":"Differences in treatment outcomes between patients with HER2-Low versus HER2-Zero, hormone receptor-positive advanced-stage breast cancer treated with ribociclib","volume":"15","author":"Sharaf","year":"2023","journal-title":"Breast Cancer Dove Med Press"},{"key":"10.1016\/j.breast.2026.104817_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.breast.2023.06.006","article-title":"The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4\/6 inhibitor and endocrine therapy: a multicentric retrospective study","volume":"70","author":"Caliskan","year":"2023","journal-title":"Breast Edinb Scotl"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-023-00534-1","article-title":"Prognostic significance of HER2-low status in HR-positive\/HER2-negative advanced breast cancer treated with CDK4\/6 inhibitors","volume":"9","author":"Zattarin","year":"2023","journal-title":"NPJ Breast Cancer"},{"issue":"12","key":"10.1016\/j.breast.2026.104817_bib30","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2026.104817_bib31","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.breast.2026.104817_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104125","article-title":"Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world","volume":"10","author":"Blondeaux","year":"2025","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.breast.2026.104817_bib33","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","article-title":"Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates","volume":"48","author":"Peduzzi","year":"1995","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"10.1016\/j.breast.2026.104817_bib34","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2026.104817_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103831","article-title":"The \u201clows\u201d: update on ER-low and HER2-low breast cancer","volume":"78","author":"Fusco","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104817_bib36","article-title":"Comprehensive diagnostic and therapeutic approaches for estrogen receptor-low breast cancer: a multidisciplinary perspective from oncologists and pathologists","author":"Zagami","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"11","key":"10.1016\/j.breast.2026.104817_bib37","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.3390\/curroncol30110706","article-title":"Estrogen-receptor-low-positive breast cancer: pathological and clinical perspectives","volume":"30","author":"Malainou","year":"2023","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104817_bib38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/curroncol33020122","article-title":"Estrogen receptor-low positive (ER-Low) breast cancer: a unique clinical and pathological entity","volume":"33","author":"Faa","year":"2026","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2026.104817_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1000704","article-title":"HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4\/6 inhibitor: a real-world study","volume":"13","author":"Shao","year":"2022","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.breast.2026.104817_bib40","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.33132","article-title":"The association of ERBB2-Low expression with the efficacy of cyclin-dependent kinase 4\/6 inhibitor in hormone receptor\u2013positive, ERBB2-Negative metastatic breast cancer","volume":"4","author":"Bao","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104817_bib41","first-page":"105","article-title":"Clinical efficacy of CDK4\/6 inhibitor plus endocrine therapy in HR-positive\/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials","author":"Li","year":"2024","journal-title":"EBioMedicine"},{"issue":"26","key":"10.1016\/j.breast.2026.104817_bib42","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1200\/JCO-25-00812","volume":"43","author":"Dilawari","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2026.104817_bib43","article-title":"Clinical and molecular evaluation of HER2-Low and ultralow breast cancer in the PENELOPE-B clinical trial cohort","volume":"21","author":"Denkert","year":"2026","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.breast.2026.104817_bib44","first-page":"924","article-title":"Investigation of the prevalence of HER2-ultralow and the effects of HER2 status (HER2-Null vs. HER2-ultralow) on survival in HER2-negative early-stage breast cancer","volume":"28","author":"T\u00fcrkel","year":"2026","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"10.1016\/j.breast.2026.104817_bib45","article-title":"Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer","volume":"46","author":"Hernandez-Hernandez","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.breast.2026.104817_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251378863","article-title":"Real-world analysis of HER2-ultralow in HR+\/HER2- metastatic breast cancer: prevalence and first-line chemotherapy outcomes","volume":"17","author":"Mathiot","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"10.1016\/j.breast.2026.104817_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105570","article-title":"Real-world progression-free survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR-positive\/HER2-negative metastatic breast cancer in United States routine clinical practice","volume":"10","author":"Rugo","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104817_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102972","article-title":"Key decision factors in second-line therapy: expert insights on HR+\/HER2-metastatic breast cancer post-CDK4\/6 inhibitor progression","volume":"138","author":"Buonaiuto","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.breast.2026.104817_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41523-025-00802-2","article-title":"Circulating genomic landscape following cyclin-dependent kinase 4\/6 inhibitors exposure in HR +\/HER2- metastatic breast cancer: a retrospective multi-institutional consortium analysis","volume":"11","author":"Pontolillo","year":"2025","journal-title":"NPJ Breast Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096097762600127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:29:16Z","timestamp":1784928556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096097762600127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":50,"alternative-id":["S096097762600127X"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104817","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4\/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104817"}}